TNO155

TNO155

CAT N°: 32525
Price:

From 182.00 154.70

TNO155 is an orally bioavailable allosteric inhibitor of Src homology region 2 domain-containing phosphatase 2 (SHP-2; IC50 = 0.011 µM).{61227} It is selective for SHP-2 over a panel of 52 kinases and phosphatases (IC50s = >10 µM for all). TNO155 decreases phosphorylation of ERK in, and inhibits proliferation of, KYSE-520 human esophageal cancer cells (IC50s = 0.011 and 0.1 µM, respectively). It acts synergistically with dabrafenib (Item No. 16989) and trametinib (Item No. 16292) to inhibit proliferation of B-RAFV600E-expressing HT-29, RKO, and MDST8 colorectal cancer cells.{61228} TNO155 (2.5, 10, and 20 mg/kg twice per day) reduces tumor growth in a KYSE-520 mouse xenograft model.{61227}

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • (3S,4S)-8-[6-amino-5-[(2-amino-3-chloro-4-pyridinyl)thio]-2-pyrazinyl]-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine
  • Correlated keywords
    • 2360806-11-5 TNO 155 SHP2 ERKin KYSE520 B-RAFV600E BRAF V600E
  • Product Overview:
    TNO155 is an orally bioavailable allosteric inhibitor of Src homology region 2 domain-containing phosphatase 2 (SHP-2; IC50 = 0.011 µM).{61227} It is selective for SHP-2 over a panel of 52 kinases and phosphatases (IC50s = >10 µM for all). TNO155 decreases phosphorylation of ERK in, and inhibits proliferation of, KYSE-520 human esophageal cancer cells (IC50s = 0.011 and 0.1 µM, respectively). It acts synergistically with dabrafenib (Item No. 16989) and trametinib (Item No. 16292) to inhibit proliferation of B-RAFV600E-expressing HT-29, RKO, and MDST8 colorectal cancer cells.{61228} TNO155 (2.5, 10, and 20 mg/kg twice per day) reduces tumor growth in a KYSE-520 mouse xenograft model.{61227}

We also advise you